Related Experiment Video
Updated: May 7, 2025
06:09
An In Ovo Model for Testing Insulin-mimetic Compounds
Published on: April 23, 2018
9.6K
Apitherapy for diabetes mellitus: mechanisms and clinical implications
Andrés Jagua-Gualdrón1,2,3, Nicolai Andrés García-Reyes1,2,3, Roger Edwin Fernández-Bernal3,4,5
1National University of Colombia, Bogota, Colombia.
Journal of Complementary & Integrative Medicine
|January 2, 2025
Summary
Apitherapy, using beehive products, shows promise as a complementary treatment for diabetes mellitus. Research indicates it positively impacts key disease mechanisms and offers clinical benefits.
Area of Science:
- Endocrinology
- Immunology
- Complementary Medicine
Background:
- Diabetes mellitus is a complex metabolic disorder with significant health impacts and challenging complications.
- Understanding the intricate pathophysiology of diabetes is crucial for developing effective management strategies.
Purpose of the Study:
- To review and analyze recent advancements in diabetes mellitus mechanisms.
- To evaluate the effects of apitherapy on these mechanisms and assess clinical evidence.
Main Methods:
- Systematic review of preclinical and clinical studies on apitherapy for diabetes mellitus.
- Analysis of evidence on apitherapy's impact on epigenetic, inflammatory, oxidative, and metabolic factors.
Main Results:
- Apitherapy demonstrates significant effects on epigenetics, chronic inflammation, and oxidative stress.
- Evidence suggests apitherapy influences metabolic control, gut dysbiosis, and tissue remodeling in diabetes.
- Clinical data supports apitherapy's positive impact on these diabetes-related mechanisms.
Conclusions:
- Apitherapy, utilizing beehive products, is a potentially valuable therapeutic system for diabetes mellitus.
- A significant body of evidence supports the use of apitherapy as a complementary treatment.
- Apitherapy offers a promising complementary approach to managing diabetes mellitus.
Related Concept Videos
01:15Diabetes: Management and Pharmacotherapy
203
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
203
01:22Diabetes Mellitus: Overview and Type I Subtype
2.3K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.3K
01:20Pathophysiology of Diabetes
780
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
780
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
132
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
132
01:15Diabetes: Symptoms, Diagnosis, and Complications
466
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
466
01:16Insulin: Dosing Regimen and Adverse Effects
121
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
121